Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com
Novel Approaches Gain Ground in Diffuse Large B-Cell Lymphoma
February 28th 2020Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.
Read More
NICE Rejects Polatuzumab Vedotin Combo in Relapsed/Refractory DLBCL
February 27th 2020The United Kingdom’s National Institute for Health and Care Excellence has chosen not to recommend polatuzumab vedotin plus rituximab and bendamustine for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who cannot undergo hematopoietic stem cell transplant.
Read More
Breast Oncologists Aim to Address Key Unanswered Questions With Novel Research Efforts
February 26th 2020Experts from Virginia Cancer Specialists, Georgetown University, Dana-Farber Cancer Institute, and Johns Hopkins Medicine to provide insight on some of the pivotal research being conducted at their respective institutions.
Read More
Randall Ruminates on Challenges With Treating Sarcomas in AYA Patients
February 25th 2020R. Lor Randall, MD, FACS, highlights the specific challenges faced by adolescent and young adult patients with sarcomas, the importance of promoting awareness of this issue, and the resources available to improve outcomes in this population.
Read More
NICE Recommends Against Frontline Pembrolizumab/Axitinib in Advanced RCC
February 13th 2020The United Kingdom’s National Institute for Health and Care Excellence has chosen to not recommend the combination of pembrolizumab and axitinib for use in treatment-naïve adult patients with advanced renal cell carcinoma.
Read More
ASCO Names Refinement of Surgical Treatment of Cancer as Advance of the Year
February 5th 2020Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.
Read More
FDA Schedules ODAC Meeting on Ramucirumab/Erlotinib in Frontline EGFR+ NSCLC
January 30th 2020The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application for intravenous ramucirumab injection for use in combination with erlotinib in the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.
Read More
CMS Expands Coverage of NGS Diagnostic Tests for Germline Ovarian, Breast Cancers
January 29th 2020The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.
Read More
Three Biosimilars Entering US Oncology Market at Substantial Discounts
January 24th 2020Three biosimilars—bevacizumab-bvzr (Zirabev), rituximab-pvvr (Ruxience), and trastuzumab-qyyp)—will become available in the United States at a substantial discount to their reference products.
Read More
NICE Cites Uncertainty in Deciding Against Larotrectinib in NTRK Fusion+ Solid Tumors
January 18th 2020The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.
Read More
NICE Rejects Treatments for Head and Neck Cancer and AML
January 16th 2020The United Kingdom’s National Institute for Health and Care Excellence has issued guidelines recommending against pembrolizumab for use in treatment-naïve patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma whose tumors express PD-L1 with a combined positive score of ≥1.
Read More
NICE Recommends Olaparib Maintenance in Relapsed, Platinum-Sensitive Ovarian Cancer
January 16th 2020The National Institute for Health and Care Excellence has recommended the use of olaparib as a maintenance treatment in adults with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More